You are not currently logged in.

Access JSTOR through your library or other institution:


Log in through your institution.

Journal Article

Epstein-Barr Virus: Inhibition of Replication by Three New Drugs

Jung-Chung Lin, M. Carolyn Smith, Yung-Chi Cheng and Joseph S. Pagano
New Series, Vol. 221, No. 4610 (Aug. 5, 1983), pp. 578-579
Stable URL:
Page Count: 2
Were these topics helpful?
See somethings inaccurate? Let us know!

Select the topics that are inaccurate.

  • More info
  • Add to My Lists
  • Cite this Item
Preview not available
Preview not available


Epstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with three human malignancies. Acyclovir [9-(2-hydroxyethoxymethyl)guanine], the first clinically useful drug effective against replication of EBV, is without effect against latent or persistent EBV infection. Three nucleoside analogs, E-5-(2-bromovinyl)-2′-deoxyuridine, 1-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)-5-iodocytosine, and 1-(2-deoxy-2-fluoro-β -D-arabinofuranosyl)-5-methyluracil are potent inhibitors of EBV replication in vitro. Moreover, in contrast to the reversibility of viral inhibition by Acyclovir, these three drugs have prolonged effects in suppressing viral replication even after the drugs are removed from persistently infected cell cultures.

Page Thumbnails

  • Thumbnail: Page 
  • Thumbnail: Page